KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Shares Issued (2016 - 2025)

Historic Shares Issued for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $503.5 million.

  • Regeneron Pharmaceuticals' Shares Issued rose 45390.54% to $503.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $635.9 million, marking a year-over-year decrease of 5660.27%. This contributed to the annual value of $635.9 million for FY2025, which is 5660.27% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Shares Issued of $503.5 million as of Q4 2025, which was up 45390.54% from $40.3 million recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Shares Issued registered a high of $821.4 million during Q3 2021, and its lowest value of $31.5 million during Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' median Shares Issued value was $303.9 million (recorded in 2022), while the average stood at $321.9 million.
  • Data for Regeneron Pharmaceuticals' Shares Issued shows a peak YoY increase of 45390.54% (in 2025) and a maximum YoY decrease of 9280.16% (in 2025) over the last 5 years.
  • Regeneron Pharmaceuticals' Shares Issued (Quarter) stood at $542.7 million in 2021, then tumbled by 31.34% to $372.6 million in 2022, then fell by 19.22% to $301.0 million in 2023, then tumbled by 69.8% to $90.9 million in 2024, then soared by 453.91% to $503.5 million in 2025.
  • Its last three reported values are $503.5 million in Q4 2025, $40.3 million for Q3 2025, and $31.5 million during Q2 2025.